56 Atopic Dermatitis Clinical Trials in Birmingham, AL (2026)

Q: Are there atopic dermatitis clinical trials in Birmingham?

Yes, there are 56 atopic dermatitis clinical trials currently recruiting in Birmingham, AL.

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Q: Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatments, medical tests, and doctor visits are provided at no cost.

Recruiting Atopic Dermatitis Studies in Birmingham

NCT02660645Recruiting

Blue Light Cystoscopy With Cysview® Registry

Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices....

Birmingham, AL4,400 participantsPhotocure

View Study Details

NCT02693535Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or ...

Birmingham, ALPHASE24,200 participantsAmerican Society of Clinical Oncology

View Study Details

NCT05237258Recruiting

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcome...

Birmingham, ALNA2,300 participantsMassachusetts General Hospital

View Study Details

NCT05889182Recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how s...

Birmingham, ALPHASE31,328 participantsAbbVie

View Study Details

NCT06129864Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HN...

Birmingham, ALPHASE31,145 participantsAstraZeneca

View Study Details

NCT06988605Recruiting

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at ...

Birmingham, AL1,000 participantsGalderma R&D

View Study Details

NCT07290803Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey...

Birmingham, AL1,000 participantsSanofi

View Study Details

NCT06788990Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficeraf...

Birmingham, ALPHASE2650 participantsBicara Therapeutics

View Study Details

NCT06241118Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on backgroun...

Birmingham, ALPHASE3636 participantsSanofi

View Study Details

NCT01810913Recruiting

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage I...

Birmingham, ALPHASE2613 participantsNational Cancer Institute (NCI)

View Study Details

NCT06855498Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib....

Birmingham, ALPHASE3600 participantsIncyte Corporation

View Study Details

NCT04892173Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab ...

Birmingham, ALPHASE3500 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT06807281Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe ...

Birmingham, ALPHASE3500 participantsPfizer

View Study Details

NCT05208047Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two...

Birmingham, ALPHASE3482 participantsCogent Biosciences, Inc.

View Study Details

NCT05889624Recruiting

Responding With Evidence and Access for Childhood Headaches

This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world car...

Birmingham, ALNA400 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT06635785Recruiting

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors....

Birmingham, ALPHASE1387 participantsOncoC4, Inc.

View Study Details

NCT04752722Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

Birmingham, ALPHASE1350 participantsenGene, Inc.

View Study Details

NCT05995964Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash,...

Birmingham, ALPHASE2340 participantsPfizer

View Study Details

NCT07000084Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has...

Birmingham, ALPHASE3330 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT07206225Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called ...

Birmingham, ALPHASE1294 participantsPfizer

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Birmingham, ALPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT07599813Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study....

Birmingham, ALPHASE2280 participantsApollo Therapeutics Ltd

View Study Details

NCT06818643Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumor...

Birmingham, ALPHASE1270 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07198074Recruiting

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizuma...

Birmingham, ALPHASE3255 participantsNational Cancer Institute (NCI)

View Study Details

NCT06031441Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti...

Birmingham, ALPHASE1250 participantsGenentech, Inc.

View Study Details

NCT05316155Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose...

Birmingham, ALPHASE1235 participantsJanssen Research & Development, LLC

View Study Details

NCT06997029Recruiting

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer....

Birmingham, ALPHASE1234 participantsBristol-Myers Squibb

View Study Details

NCT06947993Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD)....

Birmingham, ALPHASE2224 participantsNovartis Pharmaceuticals

View Study Details

NCT05507125Recruiting

Regulation of Inflammatory Genes in Hidradenitis Suppurativa

The purpose of this protocol is to examine the cytokine profi le of pati ents with hidradeniti s suppurati va (HS) and idemechanisms responsible for post-transcripti onal regulati on of these genes. T...

Birmingham, AL200 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06389136Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants w...

Birmingham, ALPHASE3200 participantsAbbVie

View Study Details

NCT06311682Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat ...

Birmingham, ALPHASE3195 participantsLEO Pharma

View Study Details

NCT02734537Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. ...

Birmingham, ALPHASE2189 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT04671667Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with...

Birmingham, ALPHASE2188 participantsNational Cancer Institute (NCI)

View Study Details

NCT07265479Recruiting

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis....

Birmingham, ALPHASE3180 participantsOrganon and Co

View Study Details

NCT04166409Recruiting

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated lo...

Birmingham, ALPHASE3170 participantsNational Cancer Institute (NCI)

View Study Details

NCT03180268Recruiting

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by sur...

Birmingham, ALPHASE3163 participantsNRG Oncology

View Study Details

NCT06603844Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and hav...

Birmingham, ALPHASE1156 participantsCorbus Pharmaceuticals Inc.

View Study Details

NCT07309445Recruiting

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer...

Birmingham, AL150 participantsJanssen Research & Development, LLC

View Study Details

NCT06807268Recruiting

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study...

Birmingham, ALPHASE3150 participantsPfizer

View Study Details

NCT07488676Recruiting

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the ...

Birmingham, ALPHASE1150 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT05606432Recruiting

Cardiometabolic Health Intervention Using Movement-to-Music Exercise

The study aims to test the benefits of a 24-week, cardio-emphasized Movement-to-Music exercise program for reversing cardiometabolic health risk factors compared to asynchronous, standard exercise pro...

Birmingham, ALNA132 participantsUniversity of Alabama at Birmingham

View Study Details

NCT07061964Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladd...

Birmingham, ALPHASE2111 participantsNational Cancer Institute (NCI)

View Study Details

NCT07226349Recruiting

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulve...

Birmingham, ALPHASE1105 participantsBeOne Medicines

View Study Details

NCT07002034Recruiting

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adj...

Birmingham, ALPHASE2100 participantsReunion Neuroscience Inc

View Study Details

NCT03739814Recruiting

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly ...

Birmingham, ALPHASE284 participantsNational Cancer Institute (NCI)

View Study Details

NCT07298395Recruiting

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an im...

Birmingham, ALPHASE260 participantsEnveda Therapeutics

View Study Details

NCT06182072Recruiting

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gem...

Birmingham, ALPHASE146 participantsProDa BioTech, LLC

View Study Details

NCT07219212Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemo...

Birmingham, ALPHASE145 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT07213973Recruiting

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-labe...

Birmingham, ALPHASE240 participantsIncyte Corporation

View Study Details

NCT05986149Recruiting

Making Intergenerational Connections Through Arts

The purpose of the study is to evaluate the impact on older adults' wellbeing of participating in a 10-week conversation about arts and culture with an international university student whose native la...

Birmingham, AL30 participantsUniversity of Alabama at Birmingham

View Study Details

NCT04929236Recruiting

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

Birmingham, ALPHASE330 participantsOctapharma

View Study Details

NCT06867822Recruiting

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with 5-fluorouracil, irinotecan (FOLFIRI) and ...

Birmingham, ALPHASE127 participantsUniversity of Alabama at Birmingham

View Study Details

NCT04511078Recruiting

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this dru...

Birmingham, ALPHASE225 participantsUniversity of Alabama at Birmingham

View Study Details

NCT07161037Recruiting

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407....

Birmingham, ALPHASE224 participantsVertex Pharmaceuticals Incorporated

View Study Details

NCT05632562Recruiting

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

This feasibility study will assess the clinical potential of a new imaging approach to detect viable high grade glioma (HGG) in pediatric and adult patients after standard of care radiation therapy (R...

Birmingham, ALEARLY_PHASE120 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06326476Recruiting

Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa....

Birmingham, ALEARLY_PHASE112 participantsUniversity of Alabama at Birmingham

View Study Details

About Atopic Dermatitis Clinical Trials in Birmingham

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 56 atopic dermatitis clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 26,475 participants. Research is being sponsored by Photocure, American Society of Clinical Oncology, Massachusetts General Hospital and 34 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Birmingham — FAQ

Are there atopic dermatitis clinical trials in Birmingham?

Yes, there are 56 atopic dermatitis clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 56 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated July 16, 2026 from ClinicalTrials.gov